SLN
Silence Therapeutics Plc - ADR

401
Mkt Cap
$295.68M
Volume
145,388.00
52W High
$8.08
52W Low
$1.97
PE Ratio
-3.74
SLN Fundamentals
Price
$6.44
Prev Close
$6.26
Open
$6.23
50D MA
$6.43
Beta
0.63
Avg. Volume
223,422.47
EPS (Annual)
-$0.9801
P/B
3.99
Rev/Employee
$373,070.71
Loading...
Loading...
News
all
press releases
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat...
Business Wire·29d ago
News Placeholder
More News
News Placeholder
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO...
Business Wire·2mo ago
News Placeholder
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Zacks·6mo ago
News Placeholder
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet
Zacks·6mo ago
News Placeholder
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Zacks·7mo ago

Latest SLN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.